New research suggests it’s not disruptive to give radiation therapy to patients who are awaiting CAR T-cell therapy for relapsed or refractory multiple myeloma.
Patients with multiple myeloma (MM) can safely undergo radiation therapy without disrupting their plan to receive chimeric antigen receptor (CAR) T-cell therapy, according to new research. The study, presented last month at the American Society for Radiation Oncology’s annual meeting, was conducted online due to the coronavirus disease 2019 pandemic.
CAR T-cell therapy has increasingly been seen as a potential breakthrough treatment for patients with MM, as well as other types of cancers. The therapy involves reprogramming patients’ own immune cells before infusing them back into the patients, where they find and kill cancer cells.
The new study focuses on CAR T B-cell maturation antigen (CART-BCMA) treatment, which was developed at the University of Pennsylvania.
Shwetha Manjunath, MD, the study’s lead author and a resident in radiation oncology at Penn’s Perelman School of Medicine, said in a press release that although radiation has long been used to help alleviate bone pain associated with relapsed or refractory MM, it was not known whether the therapy could be safely and effectively used in patients who would eventually go on to undergo CAR T-cell therapy.
To study this question, Manjunath and colleagues retrospectively identified 25 patients who received CART-BCMA therapy. Those patients were categorized into one of 3 groups:
The first group consisted of 4 patients. None of these patients experienced severe adverse effects like cytokine release syndrome (CRS) or grade 3 or higher gastrointestinal, infectious, liver-related, or neurological toxicities. Those patients also had lower rates of grade 4 hematologic toxicities, the authors said.
Among the 8 patients who had previous radiation, 3 experienced grade 3 or higher CRS. The remaining 13 patients, none of whom had undergone radiation in the year prior to CAR T-cell infusion, had 5 cases of grade 3 or higher CRS.
The authors found no decrease in overall survival or progression-free survival among the patients who underwent radiation.
“The most important takeaway here is that bridging radiation doesn’t appear to increase the risk of CRS or neurotoxicity,” said Manjunath, in a press release. “These patients safely received bridge radiation without it affecting the efficacy of CAR T cells or the rates of toxicity.”
In fact, Manjunath said it may well be that radiation therapy actually helps the efficacy of CAR T-cell therapy.
“Our work is hypothesis generating, hinting at a potential synergism between radiation and CART-BCMA therapy, which has been reported by others in the literature,” she said, adding that future prospective trials of radiation and CART-BCMA are warranted to better understand the safety profile and long-term efficacy of the combination.
Reference
Manjunath SH, Cohen AD, Arscott WT, Maity A, Plastaras JP, Paydar I. Is bridging radiation (RT) safe in B cell maturation antigen-targeting chimeric antigen receptor T cells (CART-BCMA) therapy? Int J Radiat Oncol Biol Phys. 2020;108(suppl 3):S165-S166. doi:10.1016/j.ijrobp.2020.07.934
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More